Just out!
doi: 10.1056/NEJMoa2312695. nejm.org/doi/full/10.10…

Just to take into account cardiovascular risk in these patients and monitor them properly.

doi: 10.1016/j.clgc.2024.102066
doi: 10.1038/s41391-024-00792-5.

First-line PARP inhibitors plus new hormonal agents review. Open bar for all? Population selection? Monotherapy or combination after HS-status?. Side effects management? Waiting to exhale…
doi: 10.1016/j.ctrv.2024.102726

Just landed and pleased with how much we always learn from all of you! Excellent programme, innovative dynamics and current hot topics discussion. Looking forward to seeing you soon!! David Lorente Alfonso Gómez de Liaño Guillermo de Velasco

IPARP: exclusively for BRCA?
US FDA pooled analysis,
✅BRCA1(n=64),PFSHR 0.51,OSHR 0.74
✅BRCA2(n=422), 0.31 and 0.66
✅CDK12(n=164), 0.50 and 0.63
✅PALB2(n=41),0.52 and 0.78
⭕️ATM(n=268), 1.05 and 1.18
⭕️CHEK2(n=172), 1.06 and 1.53
doi: 10.1200/JCO.23.02105

Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24 . Do we need to give adjuvant therapy to those as such low risk?

With Matt Galsky #EAU24 adjuvant nivolumab in bladder ca: HR 0.76 in ITT & 0.56 in PD-L1 +ve. Clinically meaningful results especially in PD-L1 +ves. No data on PD-L1-ve! OS is not yet significant but this data is impressive. ~60% relapse and 24% get subsequent IO. ~10% ⬆️tox.

And…
✅ADC Resistance mechanisms
doi: 10.1002/cac2.12387
doi: 10.3390/cancers15041278.
✅ADC sequencing
doi: 10.3390/curroncol30120743.
✅ADC bispecific. Making 1+1>2
This would be the way??
doi.org/10.1016/j.apsb…

Very exciting abstract presentation at AACR in San Diego: An innovative Trop2/Nectin4 targeted bispecific antibody drug conjugate (ADC) in bladder urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and beyond

🔍This innovative bispecific Trop2/Nectin4 targeting ADC…

Not yet enough role for checkpoint inhibitors sequencing in metastatic renal carcinoma. Now, real-world data. Awaiting Phase III TiNivo-2 results.
doi.org/10.1002/cncr.3…

Qué arte lo de “no tenerle miedo al silencio”. Todos lo tememos. Dar malas noticias es difícil, nadie te enseña, aprendes de tus mentores y adjuntos… y luego, cada uno pone su propio latido, sus propias experiencias y sus propios sentimientos. Lo peor, las despedidas…

Salitre

Yesterday we talked about this in the committee.20% of patients don’t recover testosterone in OFFafter ONperiod.Age+castration duration are main factors,sometimes influenced by local RT.But levels of recovered testosterone matter (4-6#0.06(pseudocastration)).Ask Dr Ramírez Backhaus

Pooled analysis of 573 patients with high-risk resectable melanoma receiving neoadjuvant treatment in 6 clinical trials. Looking for the optimal regimen.
ja.ma/3IUDzbg

Thursday gift. Turn it up! youtu.be/eiDiKwbGfIY?si…

We had no doubts but also no proof. Now it is reflected.

Cerramos la segunda temporada de #GUSpot , el punto de encuentro sobre cáncer genitourinario, abordado desde diversas especialidades.
¡Gracias a todos los expertos que lo han hecho posible! 👏

Jesus Garcia-Donas, Néstor Guerra, Teresa Alonso Gordoa , Soraya Casla, MJosé Juan,…

Estimados resis:13 adjuntos os esperan el 4 de abril en la Jornada de puertas abiertas.Nosotrs nos formamos allí y podemos contarte los entresijos. No es sólo el piloto,copiloto o tripulación,es el EQUIPO entero lo que importa.Ya tienes claro quién eliges q te guíe en este vuelo?

MODERN is open! Available at your site through the CRSU. Please help advance MRD-based adjuvant decision making in bladder cancer. Alliance for Clinical Trials in Oncology Alan Tan Ashish M. Kamat, MD, MBBS ECOG-ACRIN Cancer Research Group SWOG Cancer Research Network Guru P. Sonpavde, MD PaulCrispenMD Stephanie Berg Suzanne Cole, MD Nitin Yerram M.D. DrTylerStewart Jonathan Rosenberg MD

📢Thrilled to announce that TIDE-A trial is finally out on European Urology! Thanks to all coauthors for supporting 1️⃣st trial of TKI interruption in IO combo for #mRCC . sciencedirect.com/science/articl… Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Tom Powles Brian Rini, MD OncoAlert Università Cattolica Kidney Cancer IKCC Kidney Cancer